German medical science : GMS e-journal · 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patrij Katrin, Reiser Marcel, Wätzel Luise, Pels Hendrik, Kowoll Annika, Herrlinger Ulrich, Engert Andreas, Linnebank Michael, Schackert Gabriele, Vogt-Schaden Marlies, Egerer Gerlinde, Lamprecht Monika, Batchelor Tracy T, Schlegel Uwe, Schmidt-Wolf Ingo G H, International Primary CNS Lymphoma Collaborative Group (IPCG)
Аннотация
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin's lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003-12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1-68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).
Предметные рубрики MeSH
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCyclophosphamideCytarabineDexamethasoneDisease ProgressionDisease-Free SurvivalFemaleHumansIfosfamideKaplan-Meier EstimateLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesSalvage TherapyTreatment OutcomeVincristineVindesine